Home>>Signaling Pathways>> GPCR/G protein>> 5-HT Receptor>>Didesmethyl cariprazine

Didesmethyl cariprazine Sale

目录号 : GC62932

Didesmethyl cariprazine 是 Cariprazine 的代谢物,作为主要的循环活性部分。Didesmethyl cariprazine 的半衰期较长,为 1-3 周。Cariprazine是一种新型抗精神病候选药物,能结合 D3, D2 和 5-HT1A 。

Didesmethyl cariprazine Chemical Structure

Cas No.:839712-25-3

规格 价格 库存 购买数量
5 mg
¥4,950.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

产品描述

Didesmethyl cariprazine is a metabolite of Cariprazine and acts as the predominant circulating active moiety. Didesmethyl cariprazine has a long half-life of 1-3 weeks. Cariprazine is a antipsychotic drug candidate that exhibits high affinity for the D3 and D2 receptors, and moderate affinity for the 5-HT1A receptor[1].

[1]. Citrome L, et al. Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy. Neuropsychiatr Dis Treat. 2018 Oct 5;14:2563-2577.

Chemical Properties

Cas No. 839712-25-3 SDF
分子式 C19H28Cl2N4O 分子量 399.36
溶解度 DMSO : 11.36 mg/mL (28.45 mM; ultrasonic and warming and heat to 80°C) 储存条件
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 2.504 mL 12.52 mL 25.0401 mL
5 mM 0.5008 mL 2.504 mL 5.008 mL
10 mM 0.2504 mL 1.252 mL 2.504 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置

Research Update

Review of cariprazine in management of psychiatric illness

Ment Health Clin 2018 Mar 23;7(5):221-229.PMID:29955527DOI:10.9740/mhc.2017.09.221.

Schizophrenia and bipolar disorder are severe and debilitating psychiatric disorders. Despite the availability of numerous antipsychotic drugs, many patients still experience poor outcomes and treatment-limiting adverse side effects. Cariprazine is a novel antipsychotic with unique pharmacodynamic and pharmacokinetic properties. It is both a dopamine type 2 and dopamine type 3 partial agonist with 2 equipotent metabolites, desmethyl cariprazine and Didesmethyl cariprazine, of which Didesmethyl cariprazine has a half-life of 1 to 3 weeks. The objective of this article is to review the literature regarding efficacy and tolerability of cariprazine in the management of psychiatric disorders to determine its current place in therapy.